Payment overview · 2025
General Payments
$561.71
7 reported records · 6 companies
Healthcare provider profile · identity verified
Lei Liu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WICHITA, KS · NPI 1851378616
Verified facts
What the public records show
CMS Open Payments records show Lei Liu, MD received $561.71 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.99 | 22.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $124.99 | 22.2% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $121.87 | 21.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.35 | 17.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.03 | 10.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $35.48 | 6.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.71 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $98.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 80 |
| Omeprazole | Omeprazole | 309 | 75 |
| Losartan Potassium | Losartan Potassium | 228 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 45 |
| Simvastatin | Simvastatin | 160 | 37 |
| Metformin Hcl | Metformin Hcl | 156 | 40 |
| Furosemide | Furosemide | 154 | 39 |
| Gabapentin | Gabapentin | 146 | 30 |
| Montelukast Sodium | Montelukast Sodium | 144 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 41 |
| Allopurinol | Allopurinol | 137 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 49 |
| Alendronate Sodium | Alendronate Sodium | 129 | 31 |
| Potassium Chloride | Potassium Chloride | 108 | 22 |
| Lisinopril | Lisinopril | 106 | 31 |
| Tramadol Hcl | Tramadol Hcl | 103 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 17 |
| Ozempic | Semaglutide | 86 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 20 |
| Alprazolam | Alprazolam | 80 | 27 |
| Famotidine | Famotidine | 80 | 21 |
| Carvedilol | Carvedilol | 74 | 17 |
| Memantine Hcl | Memantine Hcl | 73 | 12 |
| Glimepiride | Glimepiride | 71 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 38 |
| Jardiance | Empagliflozin | 69 | 12 |
| Pregabalin | Pregabalin | 68 | 16 |
| Celecoxib | Celecoxib | 66 | 19 |
| Bupropion Xl | Bupropion Hcl | 61 | 12 |
| Synthroid | Levothyroxine Sodium | 61 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 24 |
| Cefuroxime | Cefuroxime Axetil | 54 | 41 |
| Spironolactone | Spironolactone | 54 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 15 |
| Atenolol | Atenolol | 51 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Baclofen | Baclofen | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | 11 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Temazepam | Temazepam | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 13 |
| Chlorthalidone | Chlorthalidone | 39 | 11 |
| Estradiol | Estradiol | 39 | 14 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Eliquis | Apixaban | 35 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 14 |
| Prednisone | Prednisone | 24 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 16 |
| Fluconazole | Fluconazole | 20 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Plavix | Clopidogrel Bisulfate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.71 · 7 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, CHARTIS CATHETER, EVENITY, PULMONX CHARTIS TABLET CONSOLE, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error